NCT04958876已完成1 期
Phase 1, Double-blind, Randomized, 2-Period, 2-Treatment Crossover Study to Evaluate the Safety of SP-104 Compared to Immediate Release Naltrexone Capsules in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 2
- 主要终点
- Incidence of treatment emergent adverse events
研究概览
简要总结
Evaluate the safety and tolerability of 3-day repeat-dose of SP-104 compared to naltrexone hydrochloride immediate release.
详细描述
The purpose of this trial is to evaluate the safety and tolerability of SP-104 relative to naltrexone immediate release capsules in healthy adults. The study is designed to test the hypothesis that the formulation of SP-104 will mitigate against adverse events associated with naltrexone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able and willing to read, write, and understand the English language and provide English language written informed consent (IC) prior to beginning any study procedures.
- •Male or female age 18 to 70 years (inclusive) at screening.
- •Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or electrocardiogram (ECG), as deemed by the Investigator.
- •Negative urine drug screen for drugs of abuse, including cocaine, marijuana, amphetamines, and barbiturates at the Screening Visit and at each check-in.
- •If female, heterosexually active, of childbearing potential, not pregnant, not trying to become pregnant, or lactating, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 30 days after the last study dose. A second non-hormonal method of contraception is required if a hormonal form of birth control is used. Females of childbearing potential must have negative pregnancy tests at Screening and on admission.
- •If male and heterosexually active, individuals are eligible to participate if participants agree to total abstinence from heterosexual intercourse, from screening through until at least 90 days after the last study dose, or to the use of an effective method listed below, from screening through until at least 90 days after the last study dose.
- •Able to swallow capsules.
- •Agrees to comply with all study requirements throughout the entire study period.
排除标准
- •A body mass index (BMI) <18 kg/m2 or >30 kg/m2 (without rounding).
- •Are using prescription medications or over-the-counter products (including dietary supplements such as vitamins, minerals, herbs or other botanicals, amino acids, enzymes (extracts or concentrates), or probiotics (bacteria or yeasts), within 14 days prior to administration of the study medication.
- •Currently using or have recently used opioids
- •Use of any other investigational drug within 30 days prior to administration of the study medication.
- •History of allergic or adverse response to naltrexone.
- •History of drug or alcohol abuse (>80 g/day).
- •History of sleep apnea or restless leg syndrome.
- •Serology positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV) antibodies.
- •Positive for known disease (e.g., corona virus disease 2019 (COVID-19 )).
- •Subjects with current or past SARS-CoV-2 infection, if tested according to local requirements.
- •Have had a serious illness in the 4 weeks preceding the Screening Visit that resulted in missed work or hospitalization (note: missed work in itself may not denote serious illness).
- •Have cancer within the past 5 years (treated or untreated).
- •Are females who are pregnant, plan to become pregnant during the study, or are breastfeeding.
- •Are an employee, family member, sponsor, or student of the Investigator or of the clinical site.
- •Are unable to understand or adhere to the requirements of the protocol.
研究组 & 干预措施
Naltrexone immediate release crossover to SP-104
Experimental
Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration
干预措施: SP-104 (Drug)
SP-104 crossover to naltrexone immediate release
Experimental
SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration
干预措施: SP-104 (Drug)
SP-104 crossover to naltrexone immediate release
Experimental
SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration
干预措施: Naltrexone immediate release oral capsules (Drug)
Naltrexone immediate release crossover to SP-104
Experimental
Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration
干预措施: Naltrexone immediate release oral capsules (Drug)
结局指标
主要结局
Incidence of treatment emergent adverse events
时间窗: 1 week
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated ObesityObesityNCT00364871Orexigen Therapeutics, Inc410
已完成
1 期
A Trial of SHR0410 Injection in Hemodialysis Participants.PruritusNCT03857568Atridia Pty Ltd.8
已完成
3 期
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROLOpioid Use DisorderNCT02696434Alkermes, Inc.101
已完成
3 期
Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHDAttention Deficit Hyperactivity DisorderNCT00556296New River Pharmaceuticals297
已完成
3 期
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsOverweightObesityNCT00532779Orexigen Therapeutics, Inc1,742